Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 8Phase 3 5Phase 1 5Phase EARLY_PHASE1 1

Status

Recruiting 3Completed 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Thoracic 1

Conditions

Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 1Advanced ER+, HER2-Negative Breast Cancer 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × elacestrant × Clear all
NCT06120283 2026-05-27

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
399 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06638307 2026-05-12

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Recruiting
240 enrolled
Breast

Advanced Breast Cancer

NCT06691035 2025-12-04

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Recruiting
18 enrolled
Breast

Breast Neoplasms

NCT02338349 2022-08-18

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Completed
57 enrolled
Breast

Advanced ER+, HER2-Negative Breast Cancer

NCT02650817 2022-08-18

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Completed
16 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡